Welcome to our dedicated page for Chemours Co SEC filings (Ticker: CC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Chemours Company (NYSE: CC) files a range of documents with the U.S. Securities and Exchange Commission that provide detailed information about its operations as a global chemistry company. Through its Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials businesses, Chemours reports segment performance, risk factors, capital structure, and environmental and legal matters in its periodic reports. On this CC filings page, investors can review those regulatory disclosures alongside AI-generated summaries that help explain key points in accessible language.
Chemours’ quarterly and annual reports discuss net sales and profitability across Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials, including trends in Opteon™ and Freon™ refrigerants, Ti-Pure™ titanium dioxide pigments, and advanced materials associated with brands such as Nafion™, Teflon™, Viton™, and Krytox™. These filings also describe the company’s global footprint, its customer and manufacturing base, and strategic priorities such as the Pathway to Thrive framework.
Current reports on Form 8-K provide updates on material events, including quarterly financial results, amendments to credit agreements, receivables purchase arrangements, environmental settlements such as the proposed judicial consent order with the State of New Jersey related to PFAS and other environmental claims, adoption of executive severance policies, and changes in board leadership. Securities registration information confirms that Chemours’ common stock trades on the New York Stock Exchange under the symbol CC.
On Stock Titan, Chemours SEC filings are updated in near real time from EDGAR and paired with AI-powered summaries that highlight important disclosures, segment commentary, and notable legal or financing developments. Users can quickly scan lengthy reports, identify items related to environmental matters, capital structure, or governance, and then drill into the original documents for full detail. This page is a resource for reviewing Chemours’ regulatory history, understanding how its three main businesses are performing, and tracking significant corporate events as they are reported to the SEC.
The Chemours Company reported changes to its board leadership. The Board of Directors has appointed Independent Director Mary Cranston as Chair of the Board and Alister Cowan as Lead Independent Director, both effective September 2, 2025. These moves follow the departure of former Chair Dawn Farrell, who has accepted a role with the Canadian government as Chief Executive Officer of the newly created Major Projects Office under the Building Canada Act. The filing confirms this is a governance update and does not discuss changes to the company’s business strategy or financial results.
The Chemours Company reported that Dawn Farrell, Chair of its Board of Directors, has decided to resign from the Board effective September 2, 2025. She is leaving to accept an appointment with the Canadian government as Chief Executive Officer of the newly created Major Projects Office launched by the Prime Minister of Canada under the Building Canada Act.
The Board received her notice on August 29, 2025, and has not yet chosen a successor as Chair. The company states that an announcement about who will become the next Board Chair will be made in the future.
The Chemours Company (CC) reporting person Will David, identified as the company's Chief Accounting Officer, reported a routine tax-withholding transaction tied to vested restricted stock units and dividend equivalent units. On 08/12/2025 2,374 shares were withheld at a price of $12.42 to satisfy tax obligations; no shares were sold and the transaction is exempt under Rule 16b-3. After the withholding, Mr. David beneficially owns 25,189.8011 shares (direct ownership). The filing includes a Power of Attorney as Exhibit 24 and was signed by an attorney-in-fact on 08/14/2025.
Denise Dignam, President & CEO and director of The Chemours Company (CC), purchased common stock on 08/08/2025. The Form 4 shows a purchase of 4,068 shares at a price of $12.06 per share, bringing her total reported beneficial ownership to 191,546.1549 shares. The filing notes the reported total includes directly owned shares, restricted stock units and dividend equivalent units.
The disclosure is a standard Section 16 insider report of a non-derivative acquisition and was submitted via Form 4. No options, conversions or derivative transactions are reported on this filing.
The Chemours Company reported an insider transaction by Shane Hostetter, its Chief Financial Officer. The filing shows 3,021 common shares were withheld to satisfy tax obligations on vesting restricted stock units and dividend equivalent units. The report indicates these withholding transactions were exempt under Rule 16b-3 and that no shares were sold in connection with the withholding.
The filing lists a per-share price of $12 for the withheld shares and shows total beneficial ownership following the transaction of 57,115.1539 shares, which the filer states includes directly owned shares, restricted stock units and dividend equivalent units.
The Schedule 13G/A for The Chemours Company shows Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander reported aggregate beneficial ownership of 7,576,095 shares of Chemours common stock, equal to 5.1% of the class. The filing specifies shared voting power of 7,443,038 and shared dispositive power of 7,576,095, and reports sole voting and dispositive powers as 0.
The filing states the reporting persons "ceased to be beneficial owners of more than 5% of the outstanding Common Stock as of July 1, 2025." The amendment is signed August 7, 2025, and includes a Joint Filing Agreement as Exhibit I. No purchase prices, transaction dates, or intent to influence control are disclosed in the document.
On 08/01/2025, Chemours (CC) President & CEO Denise Dignam filed a Form 4 disclosing an automatic share withholding (Transaction Code F) tied to vested restricted stock units.
- Shares withheld: 466 common shares at $11.50, executed solely to satisfy tax obligations; no open-market sale occurred and the trade is Rule 16b-3 exempt.
- Remaining ownership: 187,478.1549 shares held directly, meaning the transaction reduced her stake by roughly 0.25%.
- Insider role: Dignam serves as both President & CEO and Director, maintaining substantial equity alignment with investors.
The event is routine, immaterial to Chemours’ capital structure and does not signal a change in insider sentiment.
FAQ
What is the current stock price of Chemours Co (CC)?
What is the market cap of Chemours Co (CC)?
